Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress

Reuters

Yesterday

Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress

Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566699161"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566699161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566699161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566699161","market":"fut","top_or_hot":-1,"title":"Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-09 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDLXytx1:1","article_id":"2566699161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566699161","pubTimestamp":1757415788,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology  Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"Nektar Therapeutics将在EADV 2025大会上展示Rezpegaldesleukin治疗特应性皮炎的有希望的2b期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n    \n\n        Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}